Tirofiban After Successful MT Recanalization in AIS

Prior treatment

• Any active bleeding within 30 days before stroke or recent bleeding (gastrointestinal, urinary, etc.);
• parenchymal organ surgery or biopsy within 14 days before stroke;

Other illness

• Allergy to tirofiban, radiocontrast agent or Nitinol materials;
• History of heparin-induced thrombocytopenia;
• The expected survival time is less than half a year (such as malignant tumors, serious heart and lung diseases, etc.);
• Other circumstances that the investigator considers inappropriate for participation in the study or that may pose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorder).
• Acute intracranial hemorrhage on CT or MRI;
• New bilateral acute stroke or intracranial multi-drainage large vessel occlusion;

Lab values

• Platelet count \< 100\*10\^9/L;
• Being on hemodialysis or peritoneal dialysis; Known severe renal insufficiency (glomerular filtration rate \&lt; 30ml/min or serum creatinine \&gt; 220μmol/L).

Other

• Intra-arterial thrombolysis;
• Tirofiban was used within 24 hours before endovascular treatment
• Women who are known to be pregnant or lactating, or have a positive pregnancy test before randomization;
• Subjects requiring hemodialysis or peritoneal dialysis or who have contraindications to angiography for any reason;
• Have participated in other interventional clinical studies that may have an impact on the outcome assessment;
• The midline shift of the brain or cerebral hernia, ventricular mass effect;
• Simple extracranial occlusion of the internal carotid artery.

• Age ≥18 years old;
• NIHSS score: 6-30;
• Symptom onset to random time of 24h, including wake-up stroke or unwitnessed stroke; The onset time of symptoms was defined as the last time of normal performance.
• mRS 0-1 before the stroke;
• Subject or legal representative can sign an informed consent form;
• Clinical symptoms caused by acute occlusion of the following sites confirmed by CTA or MRA: intracranial segment of ICA, M1 segment of middle cerebral artery, M2 trunk of middle cerebral artery;
• ASPECTS≥6 on NCCT or DWI;
• After the end of mechanical thrombectomy, the mTICI was stable at 2b/3, and there was no secondary embolism in other non-offending vessels, or the diagnostic angiography before mechanical thrombectomy showed that the occluded vessels improved to mTICI 2b/3, and no mechanical thrombectomy was planned.